Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
Objectives: We investigated the potential associations between cerebrospinal fluid (CSF) levels of total tau (T-tau) and phosphorylated tau (P-tau), short-term response to cholinesterase inhibitor (ChEI) treatment, longitudinal outcome and progression rates in Alzheimer’s disease (AD).Methods: The Swedish Alzheimer Treatment Study (SATS) is a prospective, observational, multicentre study to assess
